Compare AbCellera Biologics Inc (ABCL) vs Icl Group Ltd (ICL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Icl Group Ltd — how do they compare? AbCellera Biologics Inc trades at $7.29 (market cap $2.35B), while Icl Group Ltd trades at $5.08 (market cap $6.49B). The key difference: Icl Group Ltd is far larger — about 2.8× AbCellera Biologics Inc's market cap, and Icl Group Ltd pays a 3.85% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | ICL | |
|---|---|---|
Market Cap | $2.35B | $6.49B |
Sector | Health | Basic Materials |
52-Week High | $8.12 | $7.23 |
52-Week Low | $2.78 | $4.80 |
Enterprise Value | $1.99B | $9.06B |
Dividend Yield | — | 3.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
ICL trades at $4.95, down 1.59% on the day, with a bearish technical signal. The company reported Q1 2026 earnings of $0.11 per share, beating estimates, and announced a $0.05 dividend for H1 2026. Revenue for 2025 was $7.15B with a net income margin of 3.52%, while valuation metrics show a P/E of 24.05 and P/S of 0.88. Recent news highlights the completion of an $800 million senior notes offering to manage debt.
The outlook is mixed; strong cash flow and dividend payments provide stability, but declining profit margins and bearish analyst sentiment pose risks. Investment opportunity lies in operational improvements and potash market exposure, though investors face headwinds from raw material costs and foreign exchange volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
